Search academic texts

Information × Registration Number 0216U008216, 0114U001095 , R & D reports Title To define the cellular-molecular mechanisms of forming imunopathologiс processes for patients with the diseases of the blood system of myeloid origin popup.stage_title Head Alla Gordienko, Registration Date 26-12-2016 Organization Kiev Research Institute of Haematolojy and Blood Transfusion popup.description2 The object of study is 56 patients with MDS and 123 with AML, cells of peripheral blood and bone marrow. Methods: general clinical, hematological, immunological. It was ascertained that the decrease in blood of CD3 + lymphocytes with expression of CD28 ligand quantity , leads to development anergy on tumoral peptides. The mechanism of immunity violation in patients with AML is expression of CD33 +-blast cells the CD95 ligand, that promotes them "escape" from the immune control over realization FAS-mediated apoptosis of CD4 +-CD8 +-immunoregulatory lymphocytes with coexpression of memebran antigene CD95. Absence of coexpression CD95 ligand on CD4 +-, CD8 +-lymphocytes and hyperexpression of Bcl-2 protooncogen of tumoral cells is the mechanism of resistency formation to therapy in patients with AML and MDS. In patients with AML and MDS in a stage of transformation in AML it is observed high proliferative activity of tumoral clone cells, with expression of Кі-67 albumen. The important mechanism of resistency to therapy with therosynkinase ingibitors in patients with CML is the increase of tumoral CD33 + - myeloid cells, and CD34 +-hemopoetic cells-pregnitors, that coexpressed glykiprotein Pgp-170 and hyperexpressed protooncogen Bcl-2 in the blood and bone marrow quantity. Medical and social effect. Medicine. Product Description popup.authors Горяінова Н.В. Кубарова В.О. Перехрестенко Т.П. Третяк Н.М. Шороп Є.В. popup.nrat_date 2020-04-02 Close